𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia : Long-term follow-up of a phase 2 study

✍ Scribed by Michael Rytting; Farhad Ravandi; Elihu Estey; Jorge Cortes; Stefan Faderl; Guillermo Garcia-Manero; Sima Jeha; Souzanne Ouzounian; Sherry Pierce; Hagop Kantarjian

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
203 KB
Volume
116
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Long-term survival of patients with acut
Long-term survival of patients with acute myeloid leukemia : A third follow-up of the Fourth International Workshop on Chromosomes in Leukemia
✍ Clara D. Bloomfield; Cynthia Shuma; Linda Regal; Preben P. Philip; Dieter K. Hos πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 284 KB πŸ‘ 2 views

## Background: In 1982, the fourth international workshop on chromosomes in leukemia reviewed data prospectively collected on 716 patients with acute myeloid leukemia (aml) diagnosed between 1980 and 1982. the present study examined the extended follow-up on these patients. ## Methods: The analys

Long-term follow-up of a phase I study o
Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias
✍ Marcos de Lima; Farhad Ravandi; Munir Shahjahan; Borje Andersson; Daniel Couriel πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 77 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Decitabine is a hypomethylating agent that has activity in patients with leukemia. The authors combined decitabine with busulfan and cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation. ## METHODS Patients with high‐ris

A phase 1-2 study of a farnesyltransfera
A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome
✍ Elias Jabbour; Hagop Kantarjian; Farhad Ravandi; Guillermo Garcia-Manero; Zeev E πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 221 KB πŸ‘ 1 views

## Abstract ## BACKGROUND: The authors conducted a phase 1/2 study of tipifarnib in combination with idarubicin and cytarabine (IA) in 95 patients with previously untreated acute myeloid leukemia (AML) or high‐risk myelodysplastic syndrome. ## METHODS: Induction consisted of idarubicin 12 mg/m^2